vs

Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Armour Residential REIT, Inc. is the larger business by last-quarter revenue ($50.4M vs $27.6M, roughly 1.8× Zymeworks Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -71.0%, a 491.2% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 72.6%).

Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ARR vs ZYME — Head-to-Head

Bigger by revenue
ARR
ARR
1.8× larger
ARR
$50.4M
$27.6M
ZYME
Growing faster (revenue YoY)
ARR
ARR
+225.3% gap
ARR
297.9%
72.6%
ZYME
Higher net margin
ARR
ARR
491.2% more per $
ARR
420.2%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARR
ARR
ZYME
ZYME
Revenue
$50.4M
$27.6M
Net Profit
$211.7M
$-19.6M
Gross Margin
Operating Margin
-80.1%
Net Margin
420.2%
-71.0%
Revenue YoY
297.9%
72.6%
Net Profit YoY
555.9%
34.3%
EPS (diluted)
$2.43
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARR
ARR
ZYME
ZYME
Q4 25
$50.4M
Q3 25
$38.5M
$27.6M
Q2 25
$33.1M
$48.7M
Q1 25
$36.3M
$27.1M
Q4 24
$12.7M
$31.0M
Q3 24
$16.0M
Q2 24
$7.0M
$19.2M
Q1 24
$10.0M
Net Profit
ARR
ARR
ZYME
ZYME
Q4 25
$211.7M
Q3 25
$159.3M
$-19.6M
Q2 25
$-75.6M
$2.3M
Q1 25
$27.3M
$-22.6M
Q4 24
$-46.4M
$-23.5M
Q3 24
$-29.9M
Q2 24
$-48.4M
$-37.7M
Q1 24
$-31.7M
Operating Margin
ARR
ARR
ZYME
ZYME
Q4 25
Q3 25
-80.1%
Q2 25
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
-222.9%
Q1 24
-376.9%
Net Margin
ARR
ARR
ZYME
ZYME
Q4 25
420.2%
Q3 25
413.5%
-71.0%
Q2 25
-228.4%
4.8%
Q1 25
75.2%
-83.5%
Q4 24
-366.8%
-75.8%
Q3 24
-186.6%
Q2 24
-693.8%
-195.8%
Q1 24
-315.6%
EPS (diluted)
ARR
ARR
ZYME
ZYME
Q4 25
$2.43
Q3 25
$1.49
$-0.26
Q2 25
$-0.94
$0.03
Q1 25
$0.32
$-0.30
Q4 24
$-0.91
$-0.32
Q3 24
$-0.39
Q2 24
$-1.05
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARR
ARR
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$63.3M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
$320.1M
Total Assets
$21.0B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARR
ARR
ZYME
ZYME
Q4 25
$63.3M
Q3 25
$44.2M
$64.8M
Q2 25
$141.2M
$98.3M
Q1 25
$49.1M
$76.2M
Q4 24
$68.0M
$66.1M
Q3 24
$122.4M
Q2 24
$126.6M
$71.0M
Q1 24
$114.8M
Stockholders' Equity
ARR
ARR
ZYME
ZYME
Q4 25
$2.3B
Q3 25
$2.1B
$320.1M
Q2 25
$1.7B
$334.5M
Q1 25
$1.7B
$325.0M
Q4 24
$1.4B
$338.8M
Q3 24
$367.0M
Q2 24
$1.2B
$406.2M
Q1 24
$438.0M
Total Assets
ARR
ARR
ZYME
ZYME
Q4 25
$21.0B
Q3 25
$19.4B
$397.3M
Q2 25
$16.2B
$408.4M
Q1 25
$15.5B
$425.5M
Q4 24
$13.5B
$463.1M
Q3 24
$487.2M
Q2 24
$10.1B
$515.6M
Q1 24
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARR
ARR
ZYME
ZYME
Operating Cash FlowLast quarter
$124.2M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARR
ARR
ZYME
ZYME
Q4 25
$124.2M
Q3 25
$-37.8M
$-31.4M
Q2 25
$25.0M
$12.1M
Q1 25
$101.5M
$-3.4M
Q4 24
$261.5M
$-41.5M
Q3 24
$-5.9M
Q2 24
$27.1M
$-25.0M
Q1 24
$-37.7M
Free Cash Flow
ARR
ARR
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
ARR
ARR
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
ARR
ARR
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
ARR
ARR
ZYME
ZYME
Q4 25
0.59×
Q3 25
-0.24×
Q2 25
5.21×
Q1 25
3.71×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons